GlassScriptPhysician profile
Catherine V Laiosa
NPI 1518126101
$880.26
in general payments reported to CMS, 2019-2025
21 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $87.12 · 2023: $88.90 · 2024: $140 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $148.46 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $142.07 | 2019-2025 | Dificid, Zerbaxa, Recarbrio |
| Exact Sciences Corporation | $74.92 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $73.92 | 2024-2025 | Zepbound, Mounjaro |
| Aimmune Therapeutics, INC. | $37.53 | 2025 | Vowst |
| Janssen Biotech, INC. | $37.05 | 2019 | |
| Amgen INC. | $34.61 | 2023-2025 | Evenity, Prolia |
| Novo Nordisk INC | $34.28 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $32.31 | 2019-2025 | |
| Tetraphase Pharmaceuticals, INC. | $30.85 | 2019 | |
| Theratechnologies INC. | $30.00 | 2019 | |
| Allergan, INC. | $28.51 | 2020 | |
| Glaxosmithkline, LLC. | $28.06 | 2019-2023 | Arexvy |
| Ferring Pharmaceuticals INC. | $26.01 | 2023 | Rebyota |
| Abbott Laboratories | $24.16 | 2024 | Freestyle Libre |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $23.24 | 2019 | |
| Shionogi INC | $17.59 | 2025 | Fetroja |
| Seqirus USA INC | $17.00 | 2024 | Flucelvax, Fluad |
| Neurocrine Biosciences, INC. | $14.42 | 2020 | |
| Daiichi Sankyo INC. | $13.89 | 2019 | |
| Scilex Pharmaceuticals INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Laiosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.